ストックスクリーナーアプリを入手
149.83
1.04%
-1.57
アフターアワーズ：
149.99
0.16
+0.11%
前日終値:
$151.40
開ける：
$148.925
24時間の取引高:
5.97M
Relative Volume:
0.83
時価総額：
$185.89B
収益：
$29.42B
当期純損益:
$8.51B
株価収益率:
22.10
EPS:
6.7801
ネットキャッシュフロー:
$10.02B
1週間 パフォーマンス:
-3.32%
1か月 パフォーマンス:
+10.23%
6か月 パフォーマンス:
+30.55%
1年 パフォーマンス:
+36.27%
1日の値動き範囲:
$148.38
$152.46
1週間の範囲:
$148.38
$156.01
52週間の値動き範囲:
$93.37
$157.29
Gilead Sciences Inc Stock (GILD) Company Profile
Compare GILD vs LLY, JNJ, ABBV, AZN, NVS
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
149.83 | 187.84B | 29.42B | 8.51B | 10.02B | 6.7801 |
|
LLY
Lilly Eli Co
|
1,058.56 | 952.34B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
245.84 | 584.38B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
229.48 | 397.33B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
AZN
Astrazeneca Plc
|
204.94 | 316.57B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
164.70 | 310.40B | 54.72B | 14.02B | 15.32B | 7.1855 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-20 | 開始されました | Barclays | Equal Weight |
| 2026-02-11 | 繰り返されました | Needham | Buy |
| 2026-01-07 | 再開されました | UBS | Buy |
| 2025-11-24 | 再開されました | Truist | Buy |
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-08-19 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | アップグレード | Truist | Hold → Buy |
| 2025-07-25 | アップグレード | Needham | Hold → Buy |
| 2025-04-22 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-03-04 | 繰り返されました | Oppenheimer | Outperform |
| 2025-02-18 | アップグレード | Deutsche Bank | Hold → Buy |
| 2025-02-13 | アップグレード | DZ Bank | Hold → Buy |
| 2025-01-10 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | 再開されました | BofA Securities | Buy |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-11-14 | 開始されました | Citigroup | Buy |
| 2024-11-08 | ダウングレード | Maxim Group | Buy → Hold |
| 2024-10-21 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | 開始されました | Bernstein | Outperform |
| 2024-10-07 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | 繰り返されました | Maxim Group | Buy |
| 2024-04-24 | アップグレード | HSBC Securities | Reduce → Hold |
| 2024-02-22 | ダウングレード | Truist | Buy → Hold |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-09-08 | アップグレード | BofA Securities | Neutral → Buy |
| 2023-09-06 | 開始されました | HSBC Securities | Reduce |
| 2023-07-24 | 繰り返されました | Barclays | Equal Weight |
| 2023-05-16 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | 再開されました | Piper Sandler | Overweight |
| 2023-01-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | 再開されました | BofA Securities | Neutral |
| 2022-12-09 | ダウングレード | DZ Bank | Buy → Hold |
| 2022-10-31 | アップグレード | Barclays | Underweight → Equal Weight |
| 2022-10-28 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2022-10-28 | 繰り返されました | Cowen | Outperform |
| 2022-10-28 | 繰り返されました | JP Morgan | Overweight |
| 2022-10-28 | 繰り返されました | Jefferies | Buy |
| 2022-10-28 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-10-28 | アップグレード | Truist | Hold → Buy |
| 2022-10-28 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-10-04 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Neutral |
| 2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-02-28 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | 繰り返されました | BMO Capital Markets | Outperform |
| 2022-02-02 | 繰り返されました | BofA Securities | Neutral |
| 2022-02-02 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-02-02 | 繰り返されました | Truist | Hold |
| 2022-02-02 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-01-28 | アップグレード | Argus | Hold → Buy |
| 2022-01-06 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-12-06 | 開始されました | Goldman | Neutral |
| 2021-11-19 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | 再開されました | Piper Sandler | Neutral |
| 2021-10-20 | 再開されました | Cowen | Outperform |
| 2021-07-30 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2021-07-30 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2021-04-01 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | アップグレード | Redburn | Neutral → Buy |
| 2021-01-19 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-11-03 | 再開されました | Morgan Stanley | Equal-Weight |
| 2020-10-28 | 開始されました | UBS | Neutral |
| 2020-09-30 | 再開されました | Jefferies | Buy |
| 2020-09-15 | アップグレード | Maxim Group | Hold → Buy |
| 2020-07-31 | 繰り返されました | Credit Suisse | Neutral |
| 2020-07-31 | 繰り返されました | Morgan Stanley | Equal-Weight |
| 2020-07-31 | 繰り返されました | Piper Sandler | Overweight |
| 2020-07-31 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2020-07-31 | 繰り返されました | SunTrust | Hold |
| 2020-07-31 | 繰り返されました | Wells Fargo | Equal Weight |
| 2020-07-20 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | アップグレード | SunTrust | Sell → Hold |
| 2020-05-01 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-05-01 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | ダウングレード | SunTrust | Hold → Sell |
| 2020-04-27 | ダウングレード | UBS | Buy → Neutral |
| 2020-04-20 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | ダウングレード | CFRA | Hold → Sell |
すべてを表示
Gilead Sciences Inc (GILD) 最新ニュース
Gilead brings Arcellx fully under the fold for $7.8B - bioworld.com
Gilead’s Bictegravir/Lenacapavir Noninferiority Data Will Support Switching From Biktarvy - Citeline News & Insights
Gilead Sciences to Present at Upcoming Investor Conferences - The Joplin Globe
This Biotech Stock Is Having Its Best Day Ever. Gilead Sciences Is Buying It. - Barron's
Evercore ISI cuts Arcellx stock rating to In Line on Gilead acquisition - Investing.com
Gilead Sciences Is Acquiring Arcellx and Partnered Multiple Myeloma Drug in $7.8B Deal - MedCity News
Gilead to Acquire Arcellx in $7.8B Biotech Bet on Cancer Therapy - USA Herald
Morgan Stanley reiterates Overweight on Gilead stock after Arcellx deal - Investing.com
Gilead buying homegrown cancer therapy company Arcellx for $7.8B - The Business Journals
Gilead: Downgrade To 'Hold' Rating Despite Arcellx Acquisition (NASDAQ:GILD) - Seeking Alpha
Ropes, Wilson Sonsini Guide Gilead's $7.8B Arcellx Buy - Law360
An $8 bln pharma deal prices patent fears - Breakingviews
Gilead Sciences Expands Oncology Portfolio with Arcellx Acquisition - GuruFocus
This biotech stock is surging 78%. Gilead Sciences agrees to buy it. - MSN
Gilead Sciences Strengthens Oncology Pipeline with Major Acquisition - AD HOC NEWS
Needham Reiterates Buy Rating for Gilead Sciences (GILD) with $1 - GuruFocus
What Gilead Is Getting Through The Acquisition Of Arcellx - Seeking Alpha
Gilead Sciences (NASDAQ:GILD) Earns Buy Rating from Needham & Company LLC - MarketBeat
Top Midday Stories: Novo Obesity Drug Doesn't Meet Primary Endpoint, Stock Falls; Gilead to Acquire Arcellx for $7.8 Billion - marketscreener.com
Arcellx shares surge after Gilead announces $7.8B takeover deal - MSN
Arcellx Surges as Gilead’s $7.8B Offer Locks In a 68% Premium - Investing.com
Gilead Sciences to buy Arcellx in deal valued at $7.8 billion - MSN
Gilead to buy biotech Arcellx in deal worth up to $7.8 billion - MSN
Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion - WTVB
Gilead Sciences To Acquire Arcellx In $7.8 Billion Deal To Strengthen Cell Therapy Portfolio - Pulse 2.0
Arcellx surges after Gilead agrees to acquire the CAR-T biotech in a deal worth up to $7.8B - Quiver Quantitative
Gilead to buy Arcellx in $7.8B wager on multiple myeloma cell therapy - BioPharma Dive
Stock Movers: Gilead, Novo Nordisk, Domino's - Bloomberg
Gilead to Buy US Biotech Arcellx for Up to $7.8 Billion - Bloomberg
Gilead Sciences Acquires Arcellx, for $7.8 Billion - FinSMEs
Gilead Sciences to snap up Arcellx in near $8bn deal - Sharecast.com
Gilead to buy Arcellx for $7.8B to expand cancer therapy pipeline - Latest news from Azerbaijan
Gilead Sciences Acquires Arcellx - Contract Pharma
Why is Arcellx stock up 80% today? Gilead's $7.8B answer - TradingView
Gilead Doubles Down on CAR T With $7.8B Arcellx Acquisition - BioSpace
Arcellx stock soars 78% as Gilead agrees to $7.8B acquisition - Investing.com Australia
Gilead pays $7.8bn to take full control of promising multiple myeloma therapy - Yahoo Finance
Gilead Sciences (GILD) Announces Strategic Merger with Arcellx - GuruFocus
Gilead Buys Arcellx To Fast-Track Next-Gen Myeloma Drug - Benzinga
Gilead punts $7.8 billion on acquisition of Arcellx - The Pharma Letter
Biotech M&A heats up with Gilead-Arcellx deal - Axios
Gilead to acquire biotech Arcellx, valued at $7.8 billion - The Weekly Journal
Gilead Acquires Anito-Cel Partner Arcellx Ahead Of US FDA Decision - Citeline News & Insights
Gilead to acquire Arcellx for $7.8 billion in cash deal - Investing.com
Gilead Sciences to Acquire Arcellx in Major Cell-Therapy Deal - TipRanks
Gilead shows belief in its partner’s cancer treatment with $7.8 billion buyout - MarketWatch
Stock Movers: Gilead Sciences, Merck, Domino's - Bloomberg
Gilead to buy US biotech Arcellx for up to US$7.8 bil - The Edge Malaysia
Gilead Sciences (GILD) Secures $1.5 Billion Deal with Genhouse B - GuruFocus
Gilead Sciences to Acquire Arcellx for $115 Per Share Plus $5 CVR via Tender Offer - TradingView
Gilead to acquire Arcellx for up to $7.8B - breakingthenews.net
Gilead Sciences Inc (GILD) 財務データ
収益
当期純利益
現金流量
EPS
Gilead Sciences Inc (GILD) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Mercier Johanna | Chief Comm & Corp Aff Officer |
Feb 17 '26 |
Sale |
154.44 |
28,000 |
4,324,228 |
120,288 |
| Dickinson Andrew D | Chief Financial Officer |
Feb 17 '26 |
Sale |
154.43 |
3,000 |
463,290 |
167,779 |
16.43%
1.25%
大文字化:
|
ボリューム (24 時間):